(Q83236335)

English

Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre

scientific article published on 01 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

based on heuristic

inferred from title

author name string

Brandon A Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Mina Torabi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

117-123

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21247220%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

https://scigraph.springernature.com/pub.10.2165/11585960-000000000-00000

0 references

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management and preparedness for infusion and hypersensitivity reactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in indolent lymphoma: the single-agent pivotal trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Models of multiple sclerosis: new insights into pathophysiology and repair

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fundamentals of antibody-related therapy and diagnostics

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cells and multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OKT3 first-dose reaction: association with T cell subsets and cytokine release

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks

1 reference

https://pubmed.ncbi.nlm.nih.gov/21247220

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83236335&oldid=1758419033"